English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#sitc2023 search results

NickTscherniaMD's profile picture. Doctor of Hematology/Oncology • Physician-Scientist Early Investigator at NIH • Tweets are my own. He/him #Immunotherapy #CellTherapy #Cancer
Nick Tschernia, MD
 @NickTscherniaMD
Nov 5, 2023

Dr. Chiara Bonini from IRCCS San Raffaele, w/ nods to the late M Cheever & T Waldmann, reviews inhibitory signals impacting TCR-T tx & how we can improve anti-tumor activity of Her2-redirected TCR-T cells through CD39 disruption. #SITC2023

NickTscherniaMD's tweet image. Dr. Chiara Bonini from IRCCS San Raffaele, w/ nods to the late M Cheever & T Waldmann, reviews inhibitory signals impacting TCR-T tx & how we can improve anti-tumor activity of Her2-redirected TCR-T cells through CD39 disruption. #SITC2023
NickTscherniaMD's tweet image. Dr. Chiara Bonini from IRCCS San Raffaele, w/ nods to the late M Cheever & T Waldmann, reviews inhibitory signals impacting TCR-T tx & how we can improve anti-tumor activity of Her2-redirected TCR-T cells through CD39 disruption. #SITC2023
NickTscherniaMD's tweet image. Dr. Chiara Bonini from IRCCS San Raffaele, w/ nods to the late M Cheever & T Waldmann, reviews inhibitory signals impacting TCR-T tx & how we can improve anti-tumor activity of Her2-redirected TCR-T cells through CD39 disruption. #SITC2023
NickTscherniaMD's tweet image. Dr. Chiara Bonini from IRCCS San Raffaele, w/ nods to the late M Cheever & T Waldmann, reviews inhibitory signals impacting TCR-T tx & how we can improve anti-tumor activity of Her2-redirected TCR-T cells through CD39 disruption. #SITC2023
0
1
7
1
1K
youngkwangchae's profile picture. Medical Oncologist, Translational Physician-Scientist, Professor, Co-Director of Developmental Therapeutics Lurie Cancer Center at Northwestern University
Young Kwang Chae, MD, MPH, MBA
 @youngkwangchae
Nov 3, 2023

Shout out to Dr. Bob Schrieber who proposed the concept of cancer immunoediting and is a pioneer of personalized cancer vaccines. #SITC #sitc2023 #immunotherapies @sitcancer @jitcancer

youngkwangchae's tweet image. Shout out to Dr. Bob Schrieber who proposed the concept of cancer immunoediting and is a pioneer of personalized cancer vaccines. #SITC #sitc2023 #immunotherapies @sitcancer @jitcancer
youngkwangchae's tweet image. Shout out to Dr. Bob Schrieber who proposed the concept of cancer immunoediting and is a pioneer of personalized cancer vaccines. #SITC #sitc2023 #immunotherapies @sitcancer @jitcancer
youngkwangchae's tweet image. Shout out to Dr. Bob Schrieber who proposed the concept of cancer immunoediting and is a pioneer of personalized cancer vaccines. #SITC #sitc2023 #immunotherapies @sitcancer @jitcancer
youngkwangchae's tweet image. Shout out to Dr. Bob Schrieber who proposed the concept of cancer immunoediting and is a pioneer of personalized cancer vaccines. #SITC #sitc2023 #immunotherapies @sitcancer @jitcancer
0
8
20
0
2K
DavidHongMD's profile picture. MD Anderson Cancer Center medical oncologist, Deputy Chair of Dept. Investigational Cancer Therapeutics. Phase I clinical trials.Tweets are mine.
David S. Hong MD
 @DavidHongMD
Nov 5, 2023

Dr Dan Zhao future Pancreatic 👸@MDAndersonNews #SITC2023

DavidHongMD's tweet image. Dr Dan Zhao future Pancreatic 👸@MDAndersonNews #SITC2023
0
1
7
0
673
youngkwangchae's profile picture. Medical Oncologist, Translational Physician-Scientist, Professor, Co-Director of Developmental Therapeutics Lurie Cancer Center at Northwestern University
Young Kwang Chae, MD, MPH, MBA
 @youngkwangchae
Nov 4, 2023

Modeling tumor heterogeneity helps us to better understand mechanism of immunotherapy resistance demonstrating pockets of immune suppression. Great talk from Melissa Reeves. @sitcancer #SITC2023 #sitc #SITC23

youngkwangchae's tweet image. Modeling tumor heterogeneity helps us to better understand mechanism of immunotherapy resistance demonstrating pockets of immune suppression. Great talk from Melissa Reeves. @sitcancer #SITC2023 #sitc #SITC23
youngkwangchae's tweet image. Modeling tumor heterogeneity helps us to better understand mechanism of immunotherapy resistance demonstrating pockets of immune suppression. Great talk from Melissa Reeves. @sitcancer #SITC2023 #sitc #SITC23
youngkwangchae's tweet image. Modeling tumor heterogeneity helps us to better understand mechanism of immunotherapy resistance demonstrating pockets of immune suppression. Great talk from Melissa Reeves. @sitcancer #SITC2023 #sitc #SITC23
0
3
12
0
903
NatRevDrugDisc's profile picture. Editorial team of Nature Reviews Drug Discovery.
Nature Reviews Drug Discovery
 @NatRevDrugDisc
Nov 2, 2023

In this new analysis, the team at @CancerResearch provide an update of the global landscape of clinical trials assessing PD1 and PDL1 inhibitors, including emerging trends on the exclusion/inclusion of resistant patients nature.com/articles/d4157… #sitc2023

NatRevDrugDisc's tweet image. In this new analysis, the team at @CancerResearch provide an update of the global landscape of clinical trials assessing PD1 and PDL1 inhibitors, including emerging trends on the exclusion/inclusion of resistant patients nature.com/articles/d4157… #sitc2023
0
33
87
21
23K
alexdoan96's profile picture. @DukeU '18 → @NIH→ @Stanford MD '25 → @OpNotes Surgery Resident In a world where you can choose to be anything, choose to be kind.
Alex Doan
 @alexdoan96
Nov 14, 2023

It was an honor to present my work in the @MackallLab and @EvanWeberPhD labs at #SITC2023, catch up with friends @Dori_Na_Krzemie and @kpmueller1, and most importantly to honor my friends Milan Gambhir and Mikael Meyer who are my biggest inspirations. Thank you @sitcancer!

0
1
28
0
2K
DrSapnaPatel's profile picture. SWOG Melanoma Chair 🧬 Dr William Robinson Endowed Chair in Cancer Research @CUDeptMedicine @CUCancerCenter 🏔 Co-host @MelanomaMattersPod 🎙️ Views my own ✨️
Sapna Patel
 @DrSapnaPatel
Nov 4, 2023

✨A beautiful night @delcoronado for #SITC2023 Academy gala with friends #endcancer @sitcancer

DrSapnaPatel's tweet image. ✨A beautiful night @delcoronado for #SITC2023 Academy gala with friends #endcancer @sitcancer
DrSapnaPatel's tweet image. ✨A beautiful night @delcoronado for #SITC2023 Academy gala with friends #endcancer @sitcancer
DrSapnaPatel's tweet image. ✨A beautiful night @delcoronado for #SITC2023 Academy gala with friends #endcancer @sitcancer
DrSapnaPatel's tweet image. ✨A beautiful night @delcoronado for #SITC2023 Academy gala with friends #endcancer @sitcancer
4
4
45
1
4K
LabSadanandam's profile picture. Developed first time PDAC,PanNET, CRC subtypes;precision medicine;machinelearning;diagnosis;preclinical trial;Global Oncology; digitaltwin;entrepreneur (my own)
Anguraj Sadanandam
 @LabSadanandam
Nov 6, 2023

Congratulations to @melanieherpels from my lab @ICR_London for her well-deserved travel award to showcase a poster at #sitc2023! Our innovative bioengineered IL12 #immunotherapy showed remarkable success in eradicating breast cancer in vivo.

LabSadanandam's tweet image. Congratulations to @melanieherpels from my lab @ICR_London for her well-deserved travel award to showcase a poster at #sitc2023! Our innovative bioengineered IL12 #immunotherapy showed remarkable success in eradicating breast cancer in vivo.
0
3
16
0
3K
anqigao's profile picture. MD/PhD student @UWMSTP studying neutrophils in the tumor microenvironment | Sondel & Dinh Labs | interested in pediatric oncology & immunology
Anqi Gao
 @anqigao
Nov 4, 2023

Come talk to me about my poster on neutrophil heterogeneity in the tumor microenvironment today! #SITC2023 @sitcancer

anqigao's tweet image. Come talk to me about my poster on neutrophil heterogeneity in the tumor microenvironment today! #SITC2023 @sitcancer
0
3
25
1
4K
Zihai's profile picture. Founding Director, Pelotonia Institute for Immuno-Oncology (@OhioStatePIIO) • Deputy Director of @OSUCCC_James for Translational Research • Views My Own
Zihai Li, MD, PhD
 @Zihai
Nov 4, 2023

Dr. Kai He from @OhioStatePIIO, @OhioStateMedOnc and @OSUCCC_James presented encouraging clinical data on #gotistobart, a novel pH-sensitive anti-CTLA4 antibody at #SITC2023. A phase 3 trial has begun for non-small cell lung cancer.

Zihai's tweet image. Dr. Kai He from @OhioStatePIIO, @OhioStateMedOnc and @OSUCCC_James presented encouraging clinical data on #gotistobart, a novel pH-sensitive anti-CTLA4 antibody at #SITC2023. A phase 3 trial has begun for non-small cell lung cancer.
Zihai's tweet image. Dr. Kai He from @OhioStatePIIO, @OhioStateMedOnc and @OSUCCC_James presented encouraging clinical data on #gotistobart, a novel pH-sensitive anti-CTLA4 antibody at #SITC2023. A phase 3 trial has begun for non-small cell lung cancer.
Zihai's tweet image. Dr. Kai He from @OhioStatePIIO, @OhioStateMedOnc and @OSUCCC_James presented encouraging clinical data on #gotistobart, a novel pH-sensitive anti-CTLA4 antibody at #SITC2023. A phase 3 trial has begun for non-small cell lung cancer.
1
5
30
0
3K
CancerInsider's profile picture. 18-year stage IV rectal cancer survivor, past Colon Club President, Double-Ostomate. DM or tweet me w/your cancer questions or experiences.
Phuong Gallagher
@CancerInsider
Nov 3, 2023

I’m at the #sitc2023 conference in San Diego. If you’re here, DM me and let’s meet up!

CancerInsider's tweet image. I’m at the #sitc2023 conference in San Diego. If you’re here, DM me and let’s meet up!
1
1
19
0
943
antgiorda's profile picture. Breast Medical Oncologist @harvardmed @DanaFarber driven by passion for #research and the one for taking care of #breastcancer patients #bcsm 🇮🇹🇺🇸
Antonio Giordano, MD PhD
 @antgiorda
Nov 3, 2023

How to better boost immunotherapy for breast cancer? From the author of TONIC trial @lab_kok a correlation between eosinophil counts and functionality with response to ICB #SITC2023 #bcsm

antgiorda's tweet image. How to better boost immunotherapy for breast cancer? From the author of TONIC trial @lab_kok a correlation between eosinophil counts and functionality with response to ICB #SITC2023 #bcsm
antgiorda's tweet image. How to better boost immunotherapy for breast cancer? From the author of TONIC trial @lab_kok a correlation between eosinophil counts and functionality with response to ICB #SITC2023 #bcsm
0
6
27
3
3K
RPachynski's profile picture. Associate Professor, Director of GU Oncology Research, Division of Oncology, Washington University STL; Tumor immunology/immunotherapy; views my own
Russell Pachynski
 @RPachynski
Nov 3, 2023

Great Richard V Smalley Award talk by Bob Schreiber! 🎉#SITC2023 @SitemanCenter @wusm_pathology @WashUOnc @sitcancer

RPachynski's tweet image. Great Richard V Smalley Award talk by Bob Schreiber! 🎉#SITC2023 @SitemanCenter @wusm_pathology @WashUOnc @sitcancer
RPachynski's tweet image. Great Richard V Smalley Award talk by Bob Schreiber! 🎉#SITC2023 @SitemanCenter @wusm_pathology @WashUOnc @sitcancer
0
3
14
1
1K
NickTscherniaMD's profile picture. Doctor of Hematology/Oncology • Physician-Scientist Early Investigator at NIH • Tweets are my own. He/him #Immunotherapy #CellTherapy #Cancer
Nick Tschernia, MD
 @NickTscherniaMD
Nov 5, 2023

Steven Feldman, Director of Manufacturing @Stanford_CCT highlights the impact of Dasatinib and 'resting' GD2-CARs on product function, phenotype, and quality. They expand with a memory-like phenotype inc CD39 exp without impact on quality/viability. #SITC2023

NickTscherniaMD's tweet image. Steven Feldman, Director of Manufacturing @Stanford_CCT highlights the impact of Dasatinib and 'resting' GD2-CARs on product function, phenotype, and quality. They expand with a memory-like phenotype inc CD39 exp without impact on quality/viability. #SITC2023
NickTscherniaMD's tweet image. Steven Feldman, Director of Manufacturing @Stanford_CCT highlights the impact of Dasatinib and 'resting' GD2-CARs on product function, phenotype, and quality. They expand with a memory-like phenotype inc CD39 exp without impact on quality/viability. #SITC2023
NickTscherniaMD's tweet image. Steven Feldman, Director of Manufacturing @Stanford_CCT highlights the impact of Dasatinib and 'resting' GD2-CARs on product function, phenotype, and quality. They expand with a memory-like phenotype inc CD39 exp without impact on quality/viability. #SITC2023
NickTscherniaMD's tweet image. Steven Feldman, Director of Manufacturing @Stanford_CCT highlights the impact of Dasatinib and 'resting' GD2-CARs on product function, phenotype, and quality. They expand with a memory-like phenotype inc CD39 exp without impact on quality/viability. #SITC2023
0
1
15
3
1K
alexdoan96's profile picture. @DukeU '18 → @NIH→ @Stanford MD '25 → @OpNotes Surgery Resident In a world where you can choose to be anything, choose to be kind.
Alex Doan
 @alexdoan96
Nov 3, 2023

So great to catch up with friends and mentors (and finally meet @kpmueller1 in person!) at SITC 2023! Excited for a great weekend of talking science, medicine, and improving patient care #SITC2023 @sitcancer

alexdoan96's tweet image. So great to catch up with friends and mentors (and finally meet @kpmueller1 in person!) at SITC 2023! Excited for a great weekend of talking science, medicine, and improving patient care #SITC2023 @sitcancer
0
0
14
0
837
JennGuerriero's profile picture. Macrophage Enthusiast, @Brighamsurgery @DFCI_BreastOnc | #TheMyeloidNetwork Co-Founder | wife and motherx3 | views=mine
Jennifer Guerriero, PhD
 @JennGuerriero
Nov 4, 2023

When @JudithVarner2 @GabrilovichLab and I started planning the @sitcancer annual meeting premeeting #myeloid program I never have imagined how phenomenal it would turn out. Thank you faculty and @sitcancer for making this program such a success. #SITC2023

JennGuerriero's tweet image. When @JudithVarner2 @GabrilovichLab and I started planning the @sitcancer annual meeting premeeting #myeloid program I never have imagined how phenomenal it would turn out. Thank you faculty and @sitcancer for making this program such a success. #SITC2023
2
7
59
0
5K
khushmanmd's profile picture. Father, husband and associate professor/GI oncologist @ Wash U/SCC. Research interest #molecularprofiling #biomarker discovery #exosomes and #pharmacogenomics
Moh’d khushman
@khushmanmd
Nov 4, 2023

In contrast to the observations seen with NTRK fusion, NTRK VUS’s are associated with better response to immune checkpoint inhibitors. Additional work to understand why is ongoing. #SITC2023 Thank you @IglesiaMichael and co-authors

khushmanmd's tweet image. In contrast to the observations seen with NTRK fusion, NTRK VUS’s are associated with better response to immune checkpoint inhibitors. Additional work to understand why is ongoing. #SITC2023 Thank you @IglesiaMichael and co-authors
0
1
7
0
694
KlebanoffLab's profile picture. A translational research lab @MSKCancerCenter focused on the immunobiology and therapeutic potential of genetically engineered #Tcells and #TCRs. Est.2016 @NYC.
Klebanoff_Lab
 @KlebanoffLab
Nov 4, 2023

Klebanoff lab member Hannah Arkin presenting her project identifying and therapeutically targeting shared neoantigens resulting from recurrent gene fusions found in solid cancers. Hannah is applying to graduate school this year and is a rockstar. #SITC2023 #Tcellpower

KlebanoffLab's tweet image. Klebanoff lab member Hannah Arkin presenting her project identifying and therapeutically targeting shared neoantigens resulting from recurrent gene fusions found in solid cancers. Hannah is applying to graduate school this year and is a rockstar. #SITC2023 #Tcellpower
1
4
77
6
9K
SMImmunology's profile picture. I study the dance between the Immune cells, the Gut Microbiome, & Cancer during the day & explore the wonders of Brazilian Jiu-Jitsu at night. Opinions are mine
Saman Maleki, PhD 🇨🇦
 @SMImmunology
Nov 4, 2023

Great seeing friends at the @sitcancer Annual meeting conference. @Zihai @NickTscherniaMD #SITC2023

SMImmunology's tweet image. Great seeing friends at the @sitcancer Annual meeting conference. @Zihai @NickTscherniaMD #SITC2023
SMImmunology's tweet image. Great seeing friends at the @sitcancer Annual meeting conference. @Zihai @NickTscherniaMD #SITC2023
SMImmunology's tweet image. Great seeing friends at the @sitcancer Annual meeting conference. @Zihai @NickTscherniaMD #SITC2023
SMImmunology's tweet image. Great seeing friends at the @sitcancer Annual meeting conference. @Zihai @NickTscherniaMD #SITC2023
0
3
15
0
2K
OncNursingNews's profile picture. Educating Nurses & Providers
Oncology Nursing News
 @OncNursingNews
Dec 1

A new investigational breast cancer vaccine shows promise in treating triple-negative breast cancer (TNBC). Early-stage trial results presented at #SITC2023 indicate strong immune responses and good safety profile. oncnursingnews.com/view/cancer-va…

0
0
0
0
96
LarkspurBio's profile picture. Destroying tumors by targeting cancer cell fitness.
Larkspur Biosciences
 @LarkspurBio
Dec 21, 2023

2023 was quite a year of exciting milestones — from launching with our Series A and growing our team to presenting at #SITC2023 and other key conferences. Our incredible and dedicated team is at the heart of this progress, and we’re thrilled about what’s in store for 2024.

LarkspurBio's tweet image. 2023 was quite a year of exciting milestones — from launching with our Series A and growing our team to presenting at #SITC2023 and other key conferences. Our incredible and dedicated team is at the heart of this progress, and we’re thrilled about what’s in store for 2024.
0
1
2
0
48
taahir_p's profile picture. recruiter in life sciences, football fanatic
Taahir Patel
 @taahir_p
Dec 13, 2023

A look back to #SITC2023 in San Diego 👀 The SITC conference is always a great place to catch up with our clients, get up to date on the latest industry news and technological advancements within immunotherapy. Will you be there in Houston next year? #Immunotherapy #S...

0
1
0
0
40
EnableMedicine's profile picture. The complete data-to-insights platform for biological discovery. Get spatial and multimodal insights powered by AI for your next therapeutic breakthrough.
Enable Medicine
 @EnableMedicine
Dec 12, 2023

(5/) Want to learn more about this pipeline and other #analysismethods presented at #SITC2023 or already available on the Enable Cloud Platform? Reach out to our team: enablemedicine.com/services

1
0
0
0
34
vitalhongkong's profile picture. 読書、音楽、旅行にも関心があります。 　あまちゃんにはまってます。→「あまロス」中→「あまナツ」（あまちゃん懐かし症候群）中です。のんさんを応援しています。
バイタル香港
 @vitalhongkong
Dec 10, 2023

ブライトパス BrightPath SITC2023 PiggyBac transposon-mediated HER2-CAR-T cells exert anti-tumor efficacy against cholangiocarcinoma. brightpathbio.com/english/img/8c… #SITC2023 #ブライトパス #BrightPath #CCA #HER2

0
0
0
0
565
vitalhongkong's profile picture. 読書、音楽、旅行にも関心があります。 　あまちゃんにはまってます。→「あまロス」中→「あまナツ」（あまちゃん懐かし症候群）中です。のんさんを応援しています。
バイタル香港
 @vitalhongkong
Dec 10, 2023

ブライトパス（SITC2023） iPSC-derived CAR-iNKT cells targeting HER2 show prolonged tumor control and promote durable survival in a tumor xenograft model brightpathbio.com/img/ea95474800…… #SITC2023 #ブライトパス #BrightPath #HER2 #iPS

0
1
0
0
448
vitalhongkong's profile picture. 読書、音楽、旅行にも関心があります。 　あまちゃんにはまってます。→「あまロス」中→「あまナツ」（あまちゃん懐かし症候群）中です。のんさんを応援しています。
バイタル香港
 @vitalhongkong
Dec 10, 2023

ブライトパス 2023年度米国癌免疫療法学会（SITC2023）の発表内容「HER315を標的とする2個のiPS細胞由来CAR-iNKT細胞が腫瘍異種移植モデルで長期にわたる腫瘍制御を示し、持続生存を促進する」 brightpathbio.com/img/ea95474800… #SITC2023 #ブライトパス #BrightPath #HER2 #iPS

0
0
0
0
374
vitalhongkong's profile picture. 読書、音楽、旅行にも関心があります。 　あまちゃんにはまってます。→「あまロス」中→「あまナツ」（あまちゃん懐かし症候群）中です。のんさんを応援しています。
バイタル香港
 @vitalhongkong
Dec 10, 2023

ブライトパス 2023年度米国癌免疫療法学会（SITC2023）の発表内容「PiggyBacトランスポゾン媒介HER2-CAR-T細胞は胆管癌に対して抗腫瘍効果を発揮する」 brightpathbio.com/english/img/8c… #SITC2023 #ブライトパス #BrightPath #CCA #HER2

0
0
0
0
439
EnableMedicine's profile picture. The complete data-to-insights platform for biological discovery. Get spatial and multimodal insights powered by AI for your next therapeutic breakthrough.
Enable Medicine
 @EnableMedicine
Dec 5, 2023

(1/) 👉🏻 NEW #computationalmethod, PEPSI, from the @EnableMedicine team uses morphology to define macro-biological states within #spatial images. Read more below about our work, also presented at #SITC2023!

EnableMedicine's tweet image. (1/) 👉🏻 NEW #computationalmethod, PEPSI, from the @EnableMedicine team uses morphology to define macro-biological states within #spatial images. Read more below about our work, also presented at #SITC2023!
1
1
3
0
442
galvanizetx's profile picture. Transforming Energy into Therapy
Galvanize Therapeutics, Inc.
@galvanizetx
Nov 29, 2023

A pre-clinical study, which was presented at #SITC2023, suggested that adding Aliya #PulsedElectricalFields to #SystemicTherapy increases murine circulating T-cells, decreases tumor growth, and improves survival in an immune-cold metastatic mouse cancer model. This…

galvanizetx's tweet image. A pre-clinical study, which was presented at #SITC2023, suggested that adding Aliya #PulsedElectricalFields to #SystemicTherapy increases murine circulating T-cells, decreases tumor growth, and improves survival in an immune-cold metastatic mouse cancer model. This…
galvanizetx's tweet image. A pre-clinical study, which was presented at #SITC2023, suggested that adding Aliya #PulsedElectricalFields to #SystemicTherapy increases murine circulating T-cells, decreases tumor growth, and improves survival in an immune-cold metastatic mouse cancer model. This…
galvanizetx's tweet image. A pre-clinical study, which was presented at #SITC2023, suggested that adding Aliya #PulsedElectricalFields to #SystemicTherapy increases murine circulating T-cells, decreases tumor growth, and improves survival in an immune-cold metastatic mouse cancer model. This…
galvanizetx's tweet image. A pre-clinical study, which was presented at #SITC2023, suggested that adding Aliya #PulsedElectricalFields to #SystemicTherapy increases murine circulating T-cells, decreases tumor growth, and improves survival in an immune-cold metastatic mouse cancer model. This…
0
0
1
0
229
ACDbio's profile picture. Leader in single-molecule, single-cell RNA expression analysis, products & services based on proprietary RNAscope Technology. +75,000 probes. A Bio-Techne brand
Advanced Cell Diag.
 @ACDbio
Nov 29, 2023

Thank you @Indica_Labs we really enjoyed #AdvancingOurRNAscopeISH with you and #HALO image analysis on this #SITC2023 poster!

Indica_Labs's profile picture. Indica Labs is the world’s leading provider of computational pathology software and image analysis services.
Indica Labs
 @Indica_Labs
Nov 29, 2023

If you missed our collaborative poster on RNA-protein co-detection & analysis with @ACDbio at #SITC23 click the link to view online now! cdn.indicalab.com/wp-content/upl… #pathtwitter #digitalpathology #spatialbiology #AdvancingYourRNAISH #HALOai #AdvancedCellDiagnostics #IndicaLabs

Indica_Labs's tweet image. If you missed our collaborative poster on RNA-protein co-detection & analysis with @ACDbio at #SITC23 click the link to view online now! cdn.indicalab.com/wp-content/upl… #pathtwitter #digitalpathology #spatialbiology #AdvancingYourRNAISH #HALOai #AdvancedCellDiagnostics #IndicaLabs
0
1
4
0
367
0
1
3
0
230
EnableMedicine's profile picture. The complete data-to-insights platform for biological discovery. Get spatial and multimodal insights powered by AI for your next therapeutic breakthrough.
Enable Medicine
 @EnableMedicine
Nov 29, 2023

(1/) ✨ #SITC2023 Spotlight ✨ — New unsupervised segmentation approach to detect tissue structures in spatial datasets!

EnableMedicine's tweet image. (1/) ✨ #SITC2023 Spotlight ✨ — New unsupervised segmentation approach to detect tissue structures in spatial datasets!
1
0
0
0
121
ej23ny's profile picture. disclaimer: No investment advice and tweets are my opinion or research that I have done. Do your own research before investing in stock market.
Biotech
 @ej23ny
Nov 21, 2023

$MREO 🤔 hasn’t updated the November presentation probably waiting on Oncxerna news some sort of update is happening reverse merger or acquisition What’s going on with Oncxerna: 1) promising data presented at #SITC2023 November 3 2) most of management team including CEO…

ej23ny's tweet image. $MREO 🤔 hasn’t updated the November presentation probably waiting on Oncxerna news some sort of update is happening reverse merger or acquisition What’s going on with Oncxerna: 1) promising data presented at #SITC2023 November 3 2) most of management team including CEO…
ej23ny's profile picture. disclaimer: No investment advice and tweets are my opinion or research that I have done. Do your own research before investing in stock market.
Biotech
 @ej23ny
Nov 21, 2023

$MREO OncXerna I missed this great presentation at #SITC2023 November 3 poster Presented by @ExactSciences $EXAS using OncXerna Technology the Xerna™ TME Panel Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in colorectal cancer patients. Data…

ej23ny's tweet image. $MREO OncXerna I missed this great presentation at #SITC2023 November 3 poster Presented by @ExactSciences $EXAS using OncXerna Technology the Xerna™ TME Panel Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in colorectal cancer patients. Data…
1
2
14
0
7K
0
2
18
1
6K
ej23ny's profile picture. disclaimer: No investment advice and tweets are my opinion or research that I have done. Do your own research before investing in stock market.
Biotech
 @ej23ny
Nov 21, 2023

$MREO OncXerna I missed this great presentation at #SITC2023 November 3 poster Presented by @ExactSciences $EXAS using OncXerna Technology the Xerna™ TME Panel Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in colorectal cancer patients. Data…

ej23ny's tweet image. $MREO OncXerna I missed this great presentation at #SITC2023 November 3 poster Presented by @ExactSciences $EXAS using OncXerna Technology the Xerna™ TME Panel Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in colorectal cancer patients. Data…
ej23ny's profile picture. disclaimer: No investment advice and tweets are my opinion or research that I have done. Do your own research before investing in stock market.
Biotech
 @ej23ny
Nov 13, 2023

$MREO @OncXerna something is brewing new article published by @Nature genialis $MREO will be eligible up to $300 million in milestones plus royalties "In a notable application of this approach, Genialis worked with OncXerna Therapeutics to create the Xerna tumor…

ej23ny's tweet image. $MREO @OncXerna something is brewing new article published by @Nature genialis $MREO will be eligible up to $300 million in milestones plus royalties "In a notable application of this approach, Genialis worked with OncXerna Therapeutics to create the Xerna tumor…
ej23ny's tweet image. $MREO @OncXerna something is brewing new article published by @Nature genialis $MREO will be eligible up to $300 million in milestones plus royalties "In a notable application of this approach, Genialis worked with OncXerna Therapeutics to create the Xerna tumor…
ej23ny's tweet image. $MREO @OncXerna something is brewing new article published by @Nature genialis $MREO will be eligible up to $300 million in milestones plus royalties "In a notable application of this approach, Genialis worked with OncXerna Therapeutics to create the Xerna tumor…
0
2
18
1
6K
1
2
14
0
7K
CueBiopharma's profile picture. Developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease and cancer
Cue Biopharma
 @CueBiopharma
Nov 21, 2023

#ICYMI, we shared new positive data from the Phase 1 trials evaluating our lead IL-2 based drug product candidates for #HeadAndNeck cancer & Wilms’ Tumor 1 positive cancers at @sitcancer’s 38th Annual Meeting (#SITC2023). Learn more here: brnw.ch/21wED39

CueBiopharma's tweet image. #ICYMI, we shared new positive data from the Phase 1 trials evaluating our lead IL-2 based drug product candidates for #HeadAndNeck cancer & Wilms’ Tumor 1 positive cancers at @sitcancer’s 38th Annual Meeting (#SITC2023). Learn more here: brnw.ch/21wED39
0
1
5
0
315
vitalhongkong's profile picture. 読書、音楽、旅行にも関心があります。 　あまちゃんにはまってます。→「あまロス」中→「あまナツ」（あまちゃん懐かし症候群）中です。のんさんを応援しています。
バイタル香港
 @vitalhongkong
Nov 21, 2023

ブライトパス 「2024年3月期第2四半期 決算説明会【動画】」掲載のお知らせ irp-system.net/presenter/?con… #SITC2023 #ブライトパス #BrightPath #iPS #HER2 #CCA

0
1
0
0
330
vitalhongkong's profile picture. 読書、音楽、旅行にも関心があります。 　あまちゃんにはまってます。→「あまロス」中→「あまナツ」（あまちゃん懐かし症候群）中です。のんさんを応援しています。
バイタル香港
 @vitalhongkong
Nov 19, 2023

BrightPath Biotherapeutics　ブライトパス November 1, 2022 BrightPath Exercised the Option to Obtain Exclusive Development, Manufacturing and Marketing License for iPS-NKT from RIKEN brightpathbio.com/english/ir/202… #SITC2023 #ブライトパス #BrightPath #iPS brightpathbio.com/english/

0
1
0
0
396
vitalhongkong's profile picture. 読書、音楽、旅行にも関心があります。 　あまちゃんにはまってます。→「あまロス」中→「あまナツ」（あまちゃん懐かし症候群）中です。のんさんを応援しています。
バイタル香港
 @vitalhongkong
Nov 19, 2023

ブライトパス SITC 2023　Abstract iPSC-derived CAR-iNKT cells targeting HER2 show prolonged tumor control and promote durable survival in a tumor xenograft model jitc.bmj.com/content/11/Sup…… #SITC2023 #ブライトパス #BrightPath #HER2 #iPS

0
3
0
0
204
No results for "#sitc2023"
NickTscherniaMD's profile picture. Doctor of Hematology/Oncology • Physician-Scientist Early Investigator at NIH • Tweets are my own. He/him #Immunotherapy #CellTherapy #Cancer
Nick Tschernia, MD
 @NickTscherniaMD
Nov 5, 2023

Dr. Chiara Bonini from IRCCS San Raffaele, w/ nods to the late M Cheever & T Waldmann, reviews inhibitory signals impacting TCR-T tx & how we can improve anti-tumor activity of Her2-redirected TCR-T cells through CD39 disruption. #SITC2023

NickTscherniaMD's tweet image. Dr. Chiara Bonini from IRCCS San Raffaele, w/ nods to the late M Cheever & T Waldmann, reviews inhibitory signals impacting TCR-T tx & how we can improve anti-tumor activity of Her2-redirected TCR-T cells through CD39 disruption. #SITC2023
NickTscherniaMD's tweet image. Dr. Chiara Bonini from IRCCS San Raffaele, w/ nods to the late M Cheever & T Waldmann, reviews inhibitory signals impacting TCR-T tx & how we can improve anti-tumor activity of Her2-redirected TCR-T cells through CD39 disruption. #SITC2023
NickTscherniaMD's tweet image. Dr. Chiara Bonini from IRCCS San Raffaele, w/ nods to the late M Cheever & T Waldmann, reviews inhibitory signals impacting TCR-T tx & how we can improve anti-tumor activity of Her2-redirected TCR-T cells through CD39 disruption. #SITC2023
NickTscherniaMD's tweet image. Dr. Chiara Bonini from IRCCS San Raffaele, w/ nods to the late M Cheever & T Waldmann, reviews inhibitory signals impacting TCR-T tx & how we can improve anti-tumor activity of Her2-redirected TCR-T cells through CD39 disruption. #SITC2023
0
1
7
1
1K
youngkwangchae's profile picture. Medical Oncologist, Translational Physician-Scientist, Professor, Co-Director of Developmental Therapeutics Lurie Cancer Center at Northwestern University
Young Kwang Chae, MD, MPH, MBA
 @youngkwangchae
Nov 3, 2023

Shout out to Dr. Bob Schrieber who proposed the concept of cancer immunoediting and is a pioneer of personalized cancer vaccines. #SITC #sitc2023 #immunotherapies @sitcancer @jitcancer

youngkwangchae's tweet image. Shout out to Dr. Bob Schrieber who proposed the concept of cancer immunoediting and is a pioneer of personalized cancer vaccines. #SITC #sitc2023 #immunotherapies @sitcancer @jitcancer
youngkwangchae's tweet image. Shout out to Dr. Bob Schrieber who proposed the concept of cancer immunoediting and is a pioneer of personalized cancer vaccines. #SITC #sitc2023 #immunotherapies @sitcancer @jitcancer
youngkwangchae's tweet image. Shout out to Dr. Bob Schrieber who proposed the concept of cancer immunoediting and is a pioneer of personalized cancer vaccines. #SITC #sitc2023 #immunotherapies @sitcancer @jitcancer
youngkwangchae's tweet image. Shout out to Dr. Bob Schrieber who proposed the concept of cancer immunoediting and is a pioneer of personalized cancer vaccines. #SITC #sitc2023 #immunotherapies @sitcancer @jitcancer
0
8
20
0
2K
youngkwangchae's profile picture. Medical Oncologist, Translational Physician-Scientist, Professor, Co-Director of Developmental Therapeutics Lurie Cancer Center at Northwestern University
Young Kwang Chae, MD, MPH, MBA
 @youngkwangchae
Nov 4, 2023

Modeling tumor heterogeneity helps us to better understand mechanism of immunotherapy resistance demonstrating pockets of immune suppression. Great talk from Melissa Reeves. @sitcancer #SITC2023 #sitc #SITC23

youngkwangchae's tweet image. Modeling tumor heterogeneity helps us to better understand mechanism of immunotherapy resistance demonstrating pockets of immune suppression. Great talk from Melissa Reeves. @sitcancer #SITC2023 #sitc #SITC23
youngkwangchae's tweet image. Modeling tumor heterogeneity helps us to better understand mechanism of immunotherapy resistance demonstrating pockets of immune suppression. Great talk from Melissa Reeves. @sitcancer #SITC2023 #sitc #SITC23
youngkwangchae's tweet image. Modeling tumor heterogeneity helps us to better understand mechanism of immunotherapy resistance demonstrating pockets of immune suppression. Great talk from Melissa Reeves. @sitcancer #SITC2023 #sitc #SITC23
0
3
12
0
903
RPachynski's profile picture. Associate Professor, Director of GU Oncology Research, Division of Oncology, Washington University STL; Tumor immunology/immunotherapy; views my own
Russell Pachynski
 @RPachynski
Nov 3, 2023

Great Richard V Smalley Award talk by Bob Schreiber! 🎉#SITC2023 @SitemanCenter @wusm_pathology @WashUOnc @sitcancer

RPachynski's tweet image. Great Richard V Smalley Award talk by Bob Schreiber! 🎉#SITC2023 @SitemanCenter @wusm_pathology @WashUOnc @sitcancer
RPachynski's tweet image. Great Richard V Smalley Award talk by Bob Schreiber! 🎉#SITC2023 @SitemanCenter @wusm_pathology @WashUOnc @sitcancer
0
3
14
1
1K
LabSadanandam's profile picture. Developed first time PDAC,PanNET, CRC subtypes;precision medicine;machinelearning;diagnosis;preclinical trial;Global Oncology; digitaltwin;entrepreneur (my own)
Anguraj Sadanandam
 @LabSadanandam
Nov 6, 2023

Congratulations to @melanieherpels from my lab @ICR_London for her well-deserved travel award to showcase a poster at #sitc2023! Our innovative bioengineered IL12 #immunotherapy showed remarkable success in eradicating breast cancer in vivo.

LabSadanandam's tweet image. Congratulations to @melanieherpels from my lab @ICR_London for her well-deserved travel award to showcase a poster at #sitc2023! Our innovative bioengineered IL12 #immunotherapy showed remarkable success in eradicating breast cancer in vivo.
0
3
16
0
3K
DavidHongMD's profile picture. MD Anderson Cancer Center medical oncologist, Deputy Chair of Dept. Investigational Cancer Therapeutics. Phase I clinical trials.Tweets are mine.
David S. Hong MD
 @DavidHongMD
Nov 5, 2023

Dr Dan Zhao future Pancreatic 👸@MDAndersonNews #SITC2023

DavidHongMD's tweet image. Dr Dan Zhao future Pancreatic 👸@MDAndersonNews #SITC2023
0
1
7
0
673
brukerspatial's profile picture. Bruker Spatial Biology provides advanced spatial molecular biology solutions, instruments, assays, software, and services for life sciences research.
Bruker Spatial Biology
 @brukerspatial
Nov 3, 2023

Happening right now! At #SITC2023, head to Room 16 to hear about the GeoMx IPA Panel and see more data in action. bit.ly/3sdzIl3 #immunotherapy

brukerspatial's tweet image. Happening right now! At #SITC2023, head to Room 16 to hear about the GeoMx IPA Panel and see more data in action. bit.ly/3sdzIl3 #immunotherapy
0
4
7
0
717
antgiorda's profile picture. Breast Medical Oncologist @harvardmed @DanaFarber driven by passion for #research and the one for taking care of #breastcancer patients #bcsm 🇮🇹🇺🇸
Antonio Giordano, MD PhD
 @antgiorda
Nov 3, 2023

How to better boost immunotherapy for breast cancer? From the author of TONIC trial @lab_kok a correlation between eosinophil counts and functionality with response to ICB #SITC2023 #bcsm

antgiorda's tweet image. How to better boost immunotherapy for breast cancer? From the author of TONIC trial @lab_kok a correlation between eosinophil counts and functionality with response to ICB #SITC2023 #bcsm
antgiorda's tweet image. How to better boost immunotherapy for breast cancer? From the author of TONIC trial @lab_kok a correlation between eosinophil counts and functionality with response to ICB #SITC2023 #bcsm
0
6
27
3
3K
NeoGenomics's profile picture. One Lab. Vital Answers.
NeoGenomics
 @NeoGenomics
Nov 4, 2023

Meet Dr. Courtney Todorov. One of NeoGenomics scientists working on the next big thing in spatial biology. #SITC2023 #NeoGenomics

NeoGenomics's tweet image. Meet Dr. Courtney Todorov. One of NeoGenomics scientists working on the next big thing in spatial biology. #SITC2023 #NeoGenomics
0
1
1
0
167
NatRevDrugDisc's profile picture. Editorial team of Nature Reviews Drug Discovery.
Nature Reviews Drug Discovery
 @NatRevDrugDisc
Nov 2, 2023

In this new analysis, the team at @CancerResearch provide an update of the global landscape of clinical trials assessing PD1 and PDL1 inhibitors, including emerging trends on the exclusion/inclusion of resistant patients nature.com/articles/d4157… #sitc2023

NatRevDrugDisc's tweet image. In this new analysis, the team at @CancerResearch provide an update of the global landscape of clinical trials assessing PD1 and PDL1 inhibitors, including emerging trends on the exclusion/inclusion of resistant patients nature.com/articles/d4157… #sitc2023
0
33
87
21
23K
WPOC's profile picture. Playing Today’s Best Country in Baltimore 🎶 Jingle Y'all is back for 2025 🤠
93.1 WPOC
 @WPOC
Oct 8, 2023

This night (with @ConnerVsmith) forever. #sitc2023 #sitc23

WPOC's tweet image. This night (with @ConnerVsmith) forever. #sitc2023 #sitc23
WPOC's tweet image. This night (with @ConnerVsmith) forever. #sitc2023 #sitc23
WPOC's tweet image. This night (with @ConnerVsmith) forever. #sitc2023 #sitc23
1
0
0
0
514
anqigao's profile picture. MD/PhD student @UWMSTP studying neutrophils in the tumor microenvironment | Sondel & Dinh Labs | interested in pediatric oncology & immunology
Anqi Gao
 @anqigao
Nov 4, 2023

Come talk to me about my poster on neutrophil heterogeneity in the tumor microenvironment today! #SITC2023 @sitcancer

anqigao's tweet image. Come talk to me about my poster on neutrophil heterogeneity in the tumor microenvironment today! #SITC2023 @sitcancer
0
3
25
1
4K
JennGuerriero's profile picture. Macrophage Enthusiast, @Brighamsurgery @DFCI_BreastOnc | #TheMyeloidNetwork Co-Founder | wife and motherx3 | views=mine
Jennifer Guerriero, PhD
 @JennGuerriero
Nov 4, 2023

When @JudithVarner2 @GabrilovichLab and I started planning the @sitcancer annual meeting premeeting #myeloid program I never have imagined how phenomenal it would turn out. Thank you faculty and @sitcancer for making this program such a success. #SITC2023

JennGuerriero's tweet image. When @JudithVarner2 @GabrilovichLab and I started planning the @sitcancer annual meeting premeeting #myeloid program I never have imagined how phenomenal it would turn out. Thank you faculty and @sitcancer for making this program such a success. #SITC2023
2
7
59
0
5K
Zihai's profile picture. Founding Director, Pelotonia Institute for Immuno-Oncology (@OhioStatePIIO) • Deputy Director of @OSUCCC_James for Translational Research • Views My Own
Zihai Li, MD, PhD
 @Zihai
Nov 4, 2023

Dr. Kai He from @OhioStatePIIO, @OhioStateMedOnc and @OSUCCC_James presented encouraging clinical data on #gotistobart, a novel pH-sensitive anti-CTLA4 antibody at #SITC2023. A phase 3 trial has begun for non-small cell lung cancer.

Zihai's tweet image. Dr. Kai He from @OhioStatePIIO, @OhioStateMedOnc and @OSUCCC_James presented encouraging clinical data on #gotistobart, a novel pH-sensitive anti-CTLA4 antibody at #SITC2023. A phase 3 trial has begun for non-small cell lung cancer.
Zihai's tweet image. Dr. Kai He from @OhioStatePIIO, @OhioStateMedOnc and @OSUCCC_James presented encouraging clinical data on #gotistobart, a novel pH-sensitive anti-CTLA4 antibody at #SITC2023. A phase 3 trial has begun for non-small cell lung cancer.
Zihai's tweet image. Dr. Kai He from @OhioStatePIIO, @OhioStateMedOnc and @OSUCCC_James presented encouraging clinical data on #gotistobart, a novel pH-sensitive anti-CTLA4 antibody at #SITC2023. A phase 3 trial has begun for non-small cell lung cancer.
1
5
30
0
3K
DrSapnaPatel's profile picture. SWOG Melanoma Chair 🧬 Dr William Robinson Endowed Chair in Cancer Research @CUDeptMedicine @CUCancerCenter 🏔 Co-host @MelanomaMattersPod 🎙️ Views my own ✨️
Sapna Patel
 @DrSapnaPatel
Nov 4, 2023

✨A beautiful night @delcoronado for #SITC2023 Academy gala with friends #endcancer @sitcancer

DrSapnaPatel's tweet image. ✨A beautiful night @delcoronado for #SITC2023 Academy gala with friends #endcancer @sitcancer
DrSapnaPatel's tweet image. ✨A beautiful night @delcoronado for #SITC2023 Academy gala with friends #endcancer @sitcancer
DrSapnaPatel's tweet image. ✨A beautiful night @delcoronado for #SITC2023 Academy gala with friends #endcancer @sitcancer
DrSapnaPatel's tweet image. ✨A beautiful night @delcoronado for #SITC2023 Academy gala with friends #endcancer @sitcancer
4
4
45
1
4K
brukerspatial's profile picture. Bruker Spatial Biology provides advanced spatial molecular biology solutions, instruments, assays, software, and services for life sciences research.
Bruker Spatial Biology
 @brukerspatial
Nov 4, 2023

Thirsty for networking? Our drink line at booth 213 is the new 'meet and greet' — best conversations are happening in the queue! #SipChatRepeat 🥂🎈 #SITC2023 #GeoMx #GeoMxIPA

brukerspatial's tweet image. Thirsty for networking? Our drink line at booth 213 is the new 'meet and greet' — best conversations are happening in the queue! #SipChatRepeat 🥂🎈 #SITC2023 #GeoMx #GeoMxIPA
brukerspatial's tweet image. Thirsty for networking? Our drink line at booth 213 is the new 'meet and greet' — best conversations are happening in the queue! #SipChatRepeat 🥂🎈 #SITC2023 #GeoMx #GeoMxIPA
0
0
8
0
629
brukerspatial's profile picture. Bruker Spatial Biology provides advanced spatial molecular biology solutions, instruments, assays, software, and services for life sciences research.
Bruker Spatial Biology
 @brukerspatial
Nov 3, 2023

Today, we are at #SITC2023 and will be hosting a workshop discussing the evolution of immuno-oncology with Spatial Biology at 12:15–1:15 pm | Room 16 AB. Join us bit.ly/3QrKQ5Q! #immunooncology #spatialbiology

brukerspatial's tweet image. Today, we are at #SITC2023 and will be hosting a workshop discussing the evolution of immuno-oncology with Spatial Biology at 12:15–1:15 pm | Room 16 AB. Join us bit.ly/3QrKQ5Q! #immunooncology #spatialbiology
0
1
4
0
508
OhioStatePIIO's profile picture. Pelotonia Institute for Immuno-Oncology. A bench-to-bedside research initiative accelerating therapeutics that use the immune system to fight cancer. #PIIO
Pelotonia Institute for Immuno-Oncology
@OhioStatePIIO
Oct 11, 2023

Mark your calendars! T-Minus 3 weeks until the #PIIO presents our “Keeping the ‘IO’ in OHIO” symposium at #SITC2023 🏖️, followed by @OSUCCC_James Scarlet & Grey Reception. DM us to be kept in the loop and for registration details!

OhioStatePIIO's tweet image. Mark your calendars! T-Minus 3 weeks until the #PIIO presents our “Keeping the ‘IO’ in OHIO” symposium at #SITC2023 🏖️, followed by @OSUCCC_James Scarlet & Grey Reception. DM us to be kept in the loop and for registration details!
1
4
21
0
2K

Something went wrong.


Something went wrong.


United States Trends